RBC reiterates Adolor at outperform

Adolor Corp. was reiterated at outperform, above average risk, by RBC Capital Markets analyst Michael J. Yee following the company's disclosure in a 10-Q that management is not expecting an Advisory Committee meeting for its New Drug Application filing, based on discussions with the Food and Drug Administration. Given the study data, the analyst believes the FDA is satisfied with the filing and expects approval of alvimopan by the Nov. 9 PDUFA. Shares of the Exton, Pa.-based biopharmaceutical company were up $1.19, or 4.97%, at $25.12, on volume of 773,824 shares versus the three-month running average of 410,286 shares. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.